Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
CIG MEDIA GROUP, LP
Citação
CLINICAL COLORECTAL CANCER, v.16, n.1, p.65-72, 2017
Resumo
The efficacy and safety of adjuvant modified FLOX (combination of oxaliplatin with a bolus regimen of fluorouracil) for patients with stage III colorectal cancer were analyzed retrospectively. A total of 267 patients were included, with a 74.9% rate of a 2-year disease-free survival and a Grade >= 3 toxicity rate of 36.7%. Age 70 years or older was associated with a higher risk of Grade >= 3 adverse events, suggesting that adjuvant oxaliplatin should be restricted to patients younger than 70 years. Background: The efficacy and safety of the combination of a fluoropyrimidine with oxaliplatin for patients with stage III colorectal cancer (CRC) have been evaluated in selected patients who took part in clinical trials. We evaluated the outcomes of FLOX (bolus fluorouracil [5-FU] combined with oxaliplatin) in patients with resected stage III CRC treated in the community in a large cancer center. Patients and Methods: We performed a retrospective unicenter cohort study of all consecutive stage III CRC patients who received adjuvant chemotherapy with an mFLOX (modified FLOX) regimen. The schedule consisted of 5-FU bolus 500 mg/m(2) and bolus of leucovorin 20 mg/m(2) per week for 6 consecutive weeks and oxaliplatin 85 mg/m(2) in a 2-hour infusion at weeks 1, 3, and 5, every 8 weeks. Logistic regression multivariate analyses were used to evaluate prognostic factors for relapse at 2 years, and to investigate potential predictors of Grade >= 3 toxicity. Results: A total of 267 consecutive patients were eligible and included. The median age was 59 years and pathological stage was mostly IIIB (68.2%). With a median follow-up of 24 months, n = 67 patients (25.1%) relapsed, representing a 74.9% rate of disease-free survival at 2 years. In multivariable analyses, urgent surgery (odds ratio [OR], 1.89; 95% confidence interval [CI], 1.02-3.48; P =.042), angiolymphatic invasion (OR, 1.92; 95% CI, 1.05-3.52; P =.034), and any interruption or dose reduction of chemotherapy (OR, 2.37; 95% CI, 1.31-4.27; P =.004) were predictors of recurrence or death at 2 years. Nine patients (3.4%) died from any cause within 60 days of starting mFLOX. Grade >= 3 toxicity occurred in 98 (36.7%) patients, with diarrhea (n = 43; 16.1%) and neutropenia (n = 38; 15.3%) being the most frequent ones. Peripheral neurotoxicity Grade >= 3 occurred in 5 patients (1.8%). Age 70 years or older (OR, 5.85; 95% CI, 2.5-13.66; P <=.001) was independently associated with a higher risk of a Grade >= 3 adverse events. Conclusion: Results suggest that the effectiveness of combining oxaliplatin with bolus 5-FU in patients in the community is reasonably similar to that obtained in clinical trials. However, community patients presented a higher risk of death, especially for those who were older than 70 years. Adjuvant oxaliplatin should be used carefully and probably restricted to fit patients younger than 70 years in this setting.
Palavras-chave
Adjuvant chemotherapy, Elderly patients, Oxaliplatin, Toxicities
Referências
- Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
- Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
- Betge J, 2012, CANCER-AM CANCER SOC, V118, P628, DOI 10.1002/cncr.26310
- CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909
- GRIFFIN MR, 1987, CANCER, V60, P2318, DOI 10.1002/1097-0142(19871101)60:9<2318::AID-CNCR2820600934>3.0.CO;2-B
- Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297
- Jager E, 1996, J CLIN ONCOL, V14, P2274
- Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974
- Mamo A, 2014, J CLIN ONCOL S, V32, pe14584
- Nebuloni DR, 2013, MOL CLIN ONCOL, V1, P175
- Shayne M, 2007, CANCER, V110, P1611, DOI 10.1002/cncr.22939
- Smoragiewicz M, 2014, J CLIN ONCOL, V32
- Tominaga T, 1996, CANCER, V78, P403
- Yothers G, 2011, J CLIN ONCOL, V29, P3768, DOI 10.1200/JCO.2011.36.4539